US healthcare reform is frequently on the US presidential policy agenda.
Following the lead from his predecessors, President Obama’s controversial health insurance reform and President Trump’s public acknowledgement for the need for lower drug prices, President Biden has taken up the gauntlet and put the cost of prescription drugs front and centre.
The Value in Health May issue includes the paper “How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine?”. Finalised in December 2020, it includes: an overview of COVID-19 vaccine development; a proposal for a benefit-based advance market commitment (BBAMC) to get the vaccines needed; and proposals for future pandemic preparedness. In this blog, the authors update their thinking to take account of the events of the last 6 months.
Early access schemes enable patients in exceptional need to access therapies that are not yet available through their health system. These schemes were not designed for single-administration therapies. In a report published today, OHE authors present key considerations for developing early access schemes for single-administration therapies.
In a commentary piece recently published in Applied Health Economics and Health Policy, OHE authors discuss how the misalignment in interpretations of the term ‘unmet medical need’ by different stakeholders has led to insufficient incentives for development in areas with urgent, genuine need, and propose a new framework for developing a more consistent understanding of UMN that will increase innovation.